multiFiltratePRO System
Fresenius Medical Care Renal Therapies Group, LLC · Decision date Oct 19, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-19 for the multiFiltratePRO System, submitted by Fresenius Medical Care Renal Therapies Group, LLC of Waltham, Massachusetts. The application, K261203, was received on 04/13/2026 and is a Traditional 510(k) under regulation 876.5860, product code KDI, with the classification name Dialyzer, High Permeability With Or Without Sealed Dialysate System. The review panel and regulation medical specialty are listed as Gastroenterology/Urology.
SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record lists clinical trial NCT05339139, no third-party review, no combination product status, and no authorized predetermined change control plan. The specific components, modifications, or indications described in the submission are not stated in the available record, so the scope of what was cleared beyond the device name and classification cannot be determined from these data.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 19, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261203
- Regulatory pathway
- 510(k) premarket notification
- Product code
- KDI
- Decision code
- SESE
- Decision date
- Oct 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dialyzer, High Permeability With Or Without Sealed Dialysate System.
- Product code
- KDI
- FDA device class
- 2
FDA decision timeline
K261203 received
Application receipt date recorded by FDA.
K261203 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fresenius Medical Care Renal Therapies Group, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Waltham, MA
Sources and methodology
- Original FDA record: K261203
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records